ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last621 to 640 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Asundexian vs Apixaban: Number of Participants With Composite of Disabling Stroke (mRS ≥ 3), Critical Bleeding, or All-cause Mortality51 of 7,373

56 of 7,364

-0.1 points

-0.3 to 0.2

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Hemorrhagic Stroke1 of 7,373

6 of 7,364

-0.1 points

-0.2 to 0.0

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: deaths from any cause73 of 7,373

85 of 7,364

-0.2 points

-0.5 to 0.2

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding83 of 7,373

188 of 7,364

-1.4 points

-1.9 to -1.0

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Asundexian vs Apixaban: serious adverse events582 of 7,373

599 of 7,364

-0.2 points

-1.1 to 0.6

14,737NCT05643573

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Exenatide Once Weekly vs Placebo: deaths from any cause507 of 7,344

584 of 7,372

-1.0 points

-1.9 to -0.2

14,716NCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Exenatide Once Weekly vs Placebo: serious adverse events1,234 of 7,344

1,222 of 7,372

0.2 points

-1.0 to 1.4

14,716NCT01144338

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

EHR-based Referral to Quit Line vs Fax-based Referral to Quit Line: Number of Participants Self-reporting Smoking Abstinence34 of 7,481

14 of 7,155

0.3 points

0.1 to 0.5

14,636NCT02735382

EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study

EHR-based Referral to Quit Line vs Fax-based Referral to Quit Line: Number of Participants Referred1,380 of 7,481

331 of 7,155

13.8 points

12.8 to 14.8

14,636NCT02735382

EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study

EHR-based Referral to Quit Line vs Fax-based Referral to Quit Line: Number of Participants Meeting Criteria for Quality Referral400 of 7,481

121 of 7,155

3.7 points

3.1 to 4.3

14,636NCT02735382

EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study

Telmisartan vs Placebo: Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)125 of 7,306

151 of 7,283

-0.4 points

-0.8 to 0.1

14,589NCT00153062

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Intervention Arm vs Usual Care: deaths from any cause34 of 706

858 of 13,867

-1.4 points

-2.8 to 0.5

14,573NCT01609842

Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence

Intervention Arm vs Usual Care: serious adverse events99 of 706

1,782 of 13,867

1.2 points

-1.3 to 4.0

14,573NCT01609842

Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence

Sitagliptin vs Placebo: serious adverse events928 of 7,266

909 of 7,274

0.3 points

-0.8 to 1.4

14,540NCT00790205

Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)

LTFU+Control >=50YOA Group vs Historical Control >=50 YOA Group: Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall69 of 7,258

341 of 7,258

-3.7 points

-4.3 to -3.2

14,516NCT02723773

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Phase I: Observational, Mother vs Phase I: Observational, Neonate: deaths from any cause3 of 7,131

453 of 7,359

-6.1 points

-6.7 to -5.6

14,490NCT05730387

Smart Discharges for Mom & Baby

Semaglutide vs DPP4 Inhibitors: deaths from any cause24 of 7,129

44 of 7,129

-0.3 points

-0.5 to -0.1

14,258NCT05768945

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Rivaroxaban vs Warfarin: serious adverse events2,649 of 7,111

2,720 of 7,125

-0.9 points

-2.5 to 0.7

14,236NCT00403767

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Baseline (Duke) vs Post Comfort Talk® Training: No-shows (Duke)395 of 4,446

779 of 9,658

0.8 points

-0.2 to 1.8

14,104NCT02427737

Comfort Talk and Economic Outcomes in MRI

Phase I: Observational, Mother vs Phase I: Observational, Neonate: Post-natal Care Visits446 of 7,060

187 of 6,968

3.6 points

3.0 to 4.3

14,028NCT05730387

Smart Discharges for Mom & Baby

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=32

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT05643573-8b8fc6df",
        "title": "Asundexian vs Apixaban: Number of Participants With Composite of Disabling Stroke (mRS ≥ 3), Critical Bleeding, or All-cause Mortality",
        "summary": "51 of 7373 against 56 of 7364; risk difference -0.1 points, 95% interval -0.3 to 0.2; NCT05643573, A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke",
        "record": "/library/comparisons/NCT05643573-8b8fc6df",
        "nct_id": "NCT05643573",
        "kind": "outcome",
        "participants": 14737,
        "risk_difference": {
          "value": -0.0006874326684712852,
          "lower": -0.003484280081333773,
          "upper": 0.002092632516717355
        },
        "group_1": "51 of 7,373",
        "group_2": "56 of 7,364",
        "difference": "-0.1 points",
        "interval": "-0.3 to 0.2",
        "trial_title": "A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke"
      },
      {
        "id": "NCT05643573-be4436d7",
        "title": "Asundexian vs Apixaban: Number of Participants With Hemorrhagic Stroke",
        "summary": "1 of 7373 against 6 of 7364; risk difference -0.1 points, 95% interval -0.2 to 0.0; NCT05643573, A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke",
        "record": "/library/comparisons/NCT05643573-be4436d7",
        "nct_id": "NCT05643573",
        "kind": "outcome",
        "participants": 14737,
        "risk_difference": {
          "value": -0.0006791445776768341,
          "lower": -0.0016474438977877742,
          "upper": 0.00009192138127663149
        },
        "group_1": "1 of 7,373",
        "group_2": "6 of 7,364",
        "difference": "-0.1 points",
        "interval": "-0.2 to 0.0",
        "trial_title": "A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=33",
  "request_id": "dbnE-D3AWJn7NYP5"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?